Docetaxel trials for Prostate cancer

All Docetaxel trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying Docetaxel for Prostate cancer

• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 298 locations
• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  NCT06863272 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 82 locations
• A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
  NCT04633252 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 110 Years · Sex: Male · 1 location
• A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
  NCT07365995 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 30 locations
• A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
  NCT06320067 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 18 locations
• A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
  NCT05818683 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 15 locations
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07225946 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 152 locations
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 151 locations
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 281 locations
• A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
  NCT07723248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 7 locations
• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07287150 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 48 locations
• Adjuvant Chemotherapy for High Malignant Prostate Cancer
  NCT06864533 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: Male · 3 locations
• Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
  NCT05983783 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: Male · 1 location
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 395 locations
• Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
  NCT06480110 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
  NCT06473259 · Phase: Not specified · Ages: No age limits stated · Sex: Male · 3 locations
• Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
  NCT04812366 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 9 locations
• Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
  NCT06387056 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
  NCT07698535 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
  NCT07333066 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 56 locations
• Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
  NCT07590934 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: Male · 37 locations
• Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
  NCT06439225 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 14 locations
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 338 locations
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 244 locations
• Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
  NCT07358806 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
  NCT06353386 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 77 locations
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 210 locations
• The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
  NCT06520345 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 33 locations
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
  NCT06282588 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 9 locations

Common questions

How many trials study Docetaxel for Prostate cancer?

29 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.